Outcomes of tocilizumab and sarilumab for hospitalized patients with COVID-19: retrospective study
Abstract Introduction Tocilizumab (TZ) and sarilumab (SL), IL-6 receptor antagonists, were utilized during the pandemic, yet direct comparisons remain limited, particularly in resource-constrained settings facing drug shortages. Hypothesis This study aimed to evaluate whether TZ and SL yield compara...
Saved in:
Main Authors: | Ashraf Mokhtar Madkour, Ashraf Abbas El Maraghy, Boles Raafat Fadly, Ragy Mamdouh Ghaly |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2025-06-01
|
Series: | The Egyptian Journal of Bronchology |
Online Access: | https://doi.org/10.1186/s43168-025-00423-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01) -
Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
by: Alexandra A. Taube, et al.
Published: (2020-09-01) -
Safety and efficacy of tocilizumab in COVID-19: A systematic evaluation of adverse effects and therapeutic outcomes
by: Othman AlOmeir, et al.
Published: (2025-10-01) -
Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial
by: Hirsh D. Komarow, MD, et al.
Published: (2025-08-01) -
Outcome of Hospitalized Pneumonia Patients with and without COVID-19: A Retrospective Cohort Study
by: Rabab Khalil, et al.
Published: (2022-01-01)